Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata - PubMed (original) (raw)

Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata

Zekayi Kutlubay et al. Turk J Med Sci. 2020.

Abstract

Background/aim: Alopecia areata (AA) is an inflammatory disease with a genetic and autoimmune basis. Herein, it was aimed to study the efficacy and safety of an immunomodulatory therapeutic agent, diphenylcyclopropenone, while manifesting its association with histopathological features, prognostic factors, and side effects.

Materials and methods: In this retrospective study, 98 patients (60 males, 38 females) with alopecia, who were referred to the Hair Disease Polyclinic at the Department of Dermatology, between 2011 and 2015, were included. Together with medical histories and dermatological examinations, a skin biopsy for histopathological examination was conducted for all of the patients prior to therapy. Therapeutic success was evaluated on the basis of the hair regrowth percentage.

Results: Regarding the overall treatment success, 33 (34%) patients had complete response, 16 (16%) had partial response (between 50% and 99%), 27 (28%) had minimal response (between 1% and 49%), and 22 (22%) were nonresponders. Both sexs were equally represented in the outcome.

Conclusions: There was a significant relation between the severity of alopecia and the treatment outcome (P = 0.038). Patients with AA had significantly better response when compared to those with alopecia totalis and universalis. There was no statistically significant relation with other parameters, such as disease duration, age, sex, atopy history, age of onset, and histopathological features.

Keywords: diphenylcyclopropenone; topical immunotherapy; Alopecia areata.

This work is licensed under a Creative Commons Attribution 4.0 International License.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Figure 1

Figure 1

(A) Appearance of the patient before DPCP. (B) Full clinical response after 4 months of DPCP treatment.

Figure 2

Figure 2

(A) Appearance of the patient before DPCP. (B) Cosmetically acceptable response after 7 months of DPCP treatment.

Figure 3

Figure 3

(A) Appearance of the patient before DPCP. (B) Patient not responding 6 months of DPCP treatment.

Figure 4

Figure 4

(A) Mild fibrosis, HEX400. (B) Moderate degree of fibrosis, HEX400. (C) Severe fibrosis, HEX400. (D) Mild degree of lymphocyte infiltration, HEX400. (E) Moderate degree of lymphocyte infiltration, HEX400. (F) Intense lymphocyte infiltration, HEX400.

References

    1. Strazzulla LC Wang EHC Avila L Lo Sicco K Brinster N Alopecia areata: Disease characteristics, clinical evaluation, and new perspectives on pathogenesis. Journal of American Academy of Dermatology. 2018;78:1–12. - PubMed
    1. Magen E Chikovani T Waitman DA Kahan NR Association of alopecia areata with atopic dermatitis and chronic spontaneous urticaria. Allergy Asthma Proceedings. 2018;39:96–102. - PubMed
    1. Happle R Hausen BM Wiesner-Menzel L Diphencyprone in the treatment of alopecia areata. Acta Dermatology and Venereology . 1983;63:49–52. - PubMed
    1. Ito T Aoshima M Ito N Uchiyama I Sakamoto K Combination therapy with oral PUVA and corticosteroid for recalcitrant alopecia areata. Archieves of Dermatological Research. 2009;301:373–80. - PubMed
    1. Rallis E Nasiopoulou A Kouskoukis C Roussaki-Schulze A Koumantaki E Oral administration of cyclosporin A in patients with severe alopecia areata. International Journal of Tissue Reactions. 2005;27:107–110. - PubMed

MeSH terms

Substances

LinkOut - more resources